Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...

The U.S. Senate has opened debate on a $9 billion rescission bill to claw back foreign aid and other funding not aligned with ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...